Moshiur Rahman Khasru

Moshiur Rahman Khasru

Auto-generated profile, based on publicly available information

Moshiur Rahman Khasru

Department of Physical Medicine & Rehabilitation, Bangladesh College of Physicians & Surgeons, Dhaka

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2021 in Case Reports in Rheumatology
Verified
Journal Article
Open access
PDF file
MKMoshiur Rahman Khasru
Moshiur Rahman Khasru
MSMd Abu Bakar BAKAR Siddiq
Md Abu Bakar BAKAR Siddiq
KSKazi Mohammad Sayeeduzzaman
Kazi Mohammad Sayeeduzzaman
TMTangila Marzen
Tangila Marzen
ASAbul Khair Mohammad Salek
Abul Khair Mohammad Salek
A 37-year-old Bangladeshi woman presented with low back and several joints pain and swelling for months together; there was significant morning stiffness for more than two hours. Repeated abortions, dry eye, hair fall, photosensitivity, and oral ulcer were the additional complaints. Clinical examination unveiled asymmetrical peripheral and both sacroiliac joint tenderness, positive modified Schober’s test, and limited chest expansion. Schirmer’s test was positive. The history of rheumatoid arthritis (RA) and ankylosing spondylitis (AS) among 1st-degree relatives was also significant. Biochemical analysis revealed pancytopenia, raised erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), and mild microscopic proteinuria. The patient was seropositive for rheumatoid factor (RF), antibodies against cyclic citrullinated peptides (anti-CCP), antinuclear antibody (ANA), anti-Sm antibody, anti-Sjögren’s-syndrome-related antigen A and B (anti-SSA/SSB), antiphospholipid (aPL-IgG/IgM), and HLA B27; however, serum complement (C3 and C4) levels were normal. Basal cortisol level measured elevated. Besides, X-ray and MRI of lumbosacral spines demonstrated sacroiliitis. There was radiological cardiomegaly, echocardiography unveiled atrial regurgitation, and ascending aorta aneurysm. Based on the abovementioned information, RA, AS, and systemic lupus erythematosus (SLE) have been diagnosed. Moreover, the patient developed Sjogren’s syndrome (SS), antiphospholipid lipid syndrome (APS), Cushing syndrome, ascending aorta aneurysm, and atrial regurgitation. Her disease activity score for RA (DAS28), DAS for AS (ASDAS), SLE disease activity index (SLEDAI), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) scores were 3.46, 2.36, 23, and 5, respectively. The patient received hydroxychloroquine (200 mg daily), pulsed cyclophosphamide, prednisolone (20 mg in the morning), and naproxen 500 mg (twice daily). To our best knowledge, this is the first report documenting RA, AS, and SLE with secondary SS and APS.

3 February 2023 in Cureus
Verified
Journal Article
Open access
PDF file
MKMoshiur R. Khasru
Moshiur R. Khasru
ASAbu B. Siddiq
Abu B. Siddiq
TMTangila Marzen
Tangila Marzen
AHAshraful Hoque
Ashraful Hoque
AAAkm Zahir Ahmed
Akm Zahir Ahmed
TJTalukder Agm Zakaria Nazimuddin Jubery
Talukder Agm Zakaria Nazimuddin Jubery
Introduction: Mesenchymal stem cell (MSC) therapy appeared promising in knee osteoarthritis (OA). We examined if a single intra-articular (IA) autologous total stromal cells (TSC) and platelet-rich plasma (PRP) injection improved knee pain, physical function, and articular cartilage thickness in knee OA. Methods: The study was performed in the physical medicine and rehabilitation department of Bangabandhu Shaikh Mujib Medical University, Dhaka, Bangladesh. Knee OA was diagnosed according to the American College of Rheumatology criteria and randomly assigned to treatment (received TSC and PRP) and control groups. Kallgreen-Lawrance (KL) scoring system was used to grade primary knee OA. The Visual Analogue Scale (VAS, 0-10 cm) for pain, WOMAC (Western Ontario and McMaster Universities Arthritis Index) for physical function, and medial femoral condylar cartilage (MFC) thickness (millimeters) under ultrasonogram (US) were documented and compared between groups before and after treatment. Statistical Package analyzed data for Social Scientists (SPSS 22.0; IBM Corp, Armonk, NY) was used for data analysis. Pre- and post-intervention outcomes were measured using the Wilcoxon-sign test, whereas Mann-Whitney U-test calculated the difference between groups; a p-value <0.05 was considered statistically significant. Result: In the treatment group, 15 received IA-TSC and PRP preparation, and in the control group, 15 patients received no injection, but quadricep muscle-strengthening exercise. There was no significant difference between groups regarding VAS for pain, WOMAC physical function, and cartilage thickness before starting the treatment and two weeks after intervention. VAS for pain and WOMAC physical function scores improved profoundly in the treatment group after 12 and 24 weeks of intervention; the pain and physical function scores difference between groups was also significant. However, significant mean femoral cartilage thickness was not changed until the end of 24 weeks (U=175.00, p=0.009 two-tailed and U= 130.00, p=0.016 two-tailed, respectively, for right and left knee). Conclusion: Single TSC and PRP injection reduces knee pain and improves physical function and cartilage thickness in knee OA. While pain and physical function improvement happen earlier, cartilage thickness change takes more time.

1 April 2021 in Rheumatology Research
Verified
Journal Article
Open access
PDF file
MKMoshiur Rahman Khasru
Moshiur Rahman Khasru
ASAbu Bakar Siddiq
Abu Bakar Siddiq
TMTangila Marzen
Tangila Marzen
MRMm Rahman
Mm Rahman
IIIffat Islam
Iffat Islam
TATamjid Ali
Tamjid Ali
Coronavirus disease (COVID-19) started its journey around the world from Wuhan, China and gradually became a pandemic.COVID-19 often affects the respiratory system, but symptoms may include fatigue, myalgia, arthralgia, arthritis, and spine andbone pain as presenting complaints. In the present systematic search and review, we aim to highlight the musculoskeletalmanifestations during COVID-19.PubMed Central and Google Scholar search engines were searched for the key words “muscle pain”, “joint pain”, “body ache”,and “fatigue”, in Covid-19 patients.After screening, a total of 76 articles dated between January 1 and July 1, 2020 met the inclusion criteria and were included inthe study. All articles were published in English comprising 36,558 COVID-19 cases. In cross-sectional studies, fatigue wasfound in 55%, myalgia in 26%, and arthralgia in 20% of cases, respectively. In cohort studies, fatigue was found in 35%, myalgiain 15%, and arthralgia in 5%, respectively. Sporadic case reports also mention back pain, bone pain, myositis, and arthritis aspresenting symptoms of COVID-19.Fatigue was the most frequent musculoskeletal (MSK) manifestation of COVID-19 followed by myalgia and joint pain. Thefrequency of the different MSK manifestations in COVID-19 may vary widely among different geographic regions.MSK like fatigue, myalgia and arthralgia are frequent symptoms in COVID-19 patients and may vary in different countries.

23 April 2024 in F1000Research
Verified
Journal Article
Open access
PDF file
MIMohammad Tariqul Islam
Mohammad Tariqul Islam
AMAfsana Mahjabin
Afsana Mahjabin
MIMahbubul Islam
Mahbubul Islam
ATAnika Tasnim
Anika Tasnim
FKFahmida Afroz Khan
Fahmida Afroz Khan
TUTaslim Uddin
Taslim Uddin
Background The COVID-19 pandemic has affected people globally, causing widespread illness and functional limitations. Methods This cross-sectional study aimed to investigate the association between COVID-19 symptoms and the functional status of COVID-19 survivors at Bangabandhu Sheikh Mujib Medical University (BSMMU) in Bangladesh. A total of 244 COVID-19 survivors were enrolled in the study, and their symptoms and functional status were assessed using standardized questionnaires. The post-COVID-19 functional status scale (PCFS) was used to assess the entire range of functional outcomes. Results Among the participants 57.4% were male and 42.6% were female. The mean (SD) age of the patients was 44.6 ±14.7 years where 37.7% were from the 20-35 years age group. The mean duration of suffering from COVID-19 was 15.9 ±6.1 days where 61.5 % of the patients had a duration of suffering of 11-20 days. Out of the 244 patients, 40 patients had no functional limitation (grade 0 functional status in the PCFS scale) while 100 had negligible functional limitation and 14 had severe functional limitation. We found patients who were suffering from multi-symptoms were statistically significant with PCFS scale grade 4, whereas grade 1 was found to be statistically significant with only respiratory distress. There was a significant association between the duration of COVID-19 symptoms and post-COVID-19 functional status for patients who experienced symptoms for 14 days or more (p<0.05). Conclusions Considering the negative impact of COVID-19 symptoms on functional status, comprehensive care and support are required for COVID-19 survivors.

15 May 2026 in The Pharmacogenomics Journal
Verified
Journal Article
Open access
MKMoshiur Rahman Khasru
Moshiur Rahman Khasru
NJNahdia Afiifah Abdul Jalil
Nahdia Afiifah Abdul Jalil
NNNisha Nair
Nisha Nair
ABAnne Barton
Anne Barton
PMPaul Martin
Paul Martin
JBJames Bluett
James Bluett
Psoriatic arthritis (PsA) is a complex inflammatory disease characterised by a combination of cutaneous and musculoskeletal symptoms, which complicates both diagnosis and management. Despite advances in targeted therapy, the treatment of PsA remains challenging, with up to 40% of patients experiencing inadequate response. Predictive biomarkers may serve as valuable tools to help clinicians select the most appropriate therapy at the optimal time. However, despite substantial research activity, the current evidence remains inconclusive. Moreover, biomarkers that predict treatment response may differ from those that dynamically change in response to therapy. In this narrative review we therefore examine both biomarkers with potential predictive value and those that demonstrate treatment-related changes over time. Multi-omics approaches have enhanced understanding of the molecular determinants of therapeutic response. Most genetic analyses have investigated TNF inhibitor response, whereas certain transcriptomic studies highlight genes related to apoptosis and immune-mediated pathways as key contributors to therapeutic response across different treatments and throughout the treatment course. Several non-coding RNAs and protein panels have also shown promise as indicators of treatment outcome, but metabolomic studies remain scarce. Reported molecular signatures nonetheless vary widely, likely reflecting disease heterogeneity as well as differences in treatment modalities, study design, and outcome measures, and are summarised herein. Future studies integrating multi-omics and computational frameworks are essential to validate candidate biomarkers and facilitate personalised treatment strategies in PsA.

26 October 2020 in Scholars Journal of Applied Medical Sciences
Verified
Journal Article
Open access
BABadrunnesa Ahmed
Badrunnesa Ahmed
SAShafiqul Alam
Shafiqul Alam
MIMohammad Tariqul Islam
Mohammad Tariqul Islam
SASyed Mozaffar Ahmed
Syed Mozaffar Ahmed
TUTaslim Uddin
Taslim Uddin
MKMoshiur Rahman Khasru
Moshiur Rahman Khasru